Cinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: a multicentre, retrospective, 3‐year study

Media type: E-Article
Title: Cinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: a multicentre, retrospective, 3‐year study
Contributor: Torregrosa, Jose‐Vicente; Morales, Enrique; Díaz, Juan Manuel; Crespo, Josep; Bravo, Juan; Gómez, Gonzalo; Gentil, Miguel Ángel; Rodríguez Benot, Alberto; García, Minerva Rodríguez; Jiménez, Verónica López; Gutiérrez Dalmau, Alex; Jimeno, Luisa; Sáez, María José Pérez; Romero, Rafael; Gómez Alamillo, Carlos
imprint: Wiley, 2014
Published in: Nephrology
Language: English
DOI: 10.1111/nep.12186
ISSN: 1320-5358; 1440-1797
Keywords: Nephrology ; General Medicine
Origination:
Footnote:
Description: <jats:title>Abstract</jats:title><jats:sec><jats:title>Aims</jats:title><jats:p>Our aim was to evaluate the long‐term effect of cinacalcet in patients with hypercalcaemic secondary hyperparathyroidism (<jats:styled-content style="fixed-case">SHPT</jats:styled-content>) after renal transplantation (<jats:styled-content style="fixed-case">RT</jats:styled-content>) in order to expand real‐world data in this population.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We performed a multicentre, observational, retrospective study in 17 renal transplant units from <jats:styled-content style="fixed-case">S</jats:styled-content>pain. We collected data from renal recipients with hypercalcaemic (calcium >10.2 mg/dL) <jats:styled-content style="fixed-case">SHPT</jats:styled-content> (intact parathyroid hormone (iPTH) > 120 pg/mL) who initiated cinacalcet in the clinical practice.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We included 193 patients with a mean (standard deviation (<jats:styled-content style="fixed-case">SD</jats:styled-content>)) age of 52 (12) years, 58% men. Cinacalcet treatment was initiated at a median of 20 months after <jats:styled-content style="fixed-case">RT</jats:styled-content> (median dose 30 mg/day). Mean calcium levels decreased from a mean (<jats:styled-content style="fixed-case">SD</jats:styled-content>) of 11.1 (0.6) at baseline to 10.1 (0.8) at 6 months (9.0% reduction, <jats:italic>P</jats:italic> < 0.0001). Median iPTH was reduced by 23.0% at 6 months (<jats:italic>P</jats:italic> = 0.0005) and mean phosphorus levels increased by 11.1% (<jats:italic>P</jats:italic> < 0.0001). The effects were maintained up to 3‐years. No changes were observed in renal function or anticalcineurin drug levels. Only 4.1% of patients discontinued cinacalcet due to intolerance and 1.0% due to lack of efficacy.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>In renal transplant patients with hypercalcaemic <jats:styled-content style="fixed-case">SHPT</jats:styled-content>, cinacalcet controlled serum calcium, iPTH and phosphorus levels up to 3 years. Tolerability was good.</jats:p></jats:sec>

Search in field:

Recently searched for: